Literature DB >> 24535608

Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis.

Kangwu Chen1, Jianqiang Mo, Ming Zhou, Genlin Wang, Guizhong Wu, Hao Chen, Kai Zhang, Huilin Yang.   

Abstract

Sacral chordoma is an aggressive, locally invasive neoplasm, and has a poor prognosis. However, the molecular basis for the clinical behavior remains unknown. The purpose of this study was to investigate the expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and mammalian target of rapamycin (mTOR) in sacral chordoma, and explore their roles in the prognosis. PTEN and mTOR were detected immunohistochemically in 40 sacral chordoma tissues and 10 adjacent normal tissues. Correlations between PTEN and mTOR expression and clinicopathological factors were analyzed. Kaplan-Meier survival curves and log-rank test were used to analyze the continuous disease-free survival time (CDFS). The expression of PTEN in sacral chordoma was significantly lower than that in adjacent normal tissues, while the levels of mTOR expression in sacral chordoma were significantly higher than that in adjacent normal tissues (P = 0.000, P = 0.030). The positive expression of mTOR appears to correlate with the negative expression of PTEN in sacral chordoma (P = 0.021). PTEN-negative expression and mTOR-positive expression were associated with tumor invasion into the surrounding muscles (P = 0.038, P = 0.014). Log-rank test showed that PTEN-negative and mTOR-positive expressions had an important impact on the patients' CDFS (P = 0.011, P = 0.015). Our results suggest that PTEN and mTOR might play an important role in the local invasiveness of sacral chordoma. PTEN and mTOR might be recognized as important prognostic predictors of recurrence and could be used as potential therapeutic targets for the treatment for sacral chordoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24535608     DOI: 10.1007/s12032-014-0886-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  21 in total

Review 1.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

Review 2.  The mTOR pathway and its role in human genetic diseases.

Authors:  Margit Rosner; Michaela Hanneder; Nicol Siegel; Alessandro Valli; Christiane Fuchs; Markus Hengstschläger
Journal:  Mutat Res       Date:  2008-06-11       Impact factor: 2.433

3.  Operative management of sacral chordoma.

Authors:  Bruno Fuchs; Ian D Dickey; Michael J Yaszemski; Carrie Y Inwards; Franklin H Sim
Journal:  J Bone Joint Surg Am       Date:  2005-10       Impact factor: 5.284

4.  PTEN/MMAC1 mutations in endometrial cancers.

Authors:  J I Risinger; A K Hayes; A Berchuck; J C Barrett
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

5.  Expression and alterations of the PTEN / AKT / mTOR pathway in ameloblastomas.

Authors:  M A Scheper; R Chaisuparat; N G Nikitakis; J J Sauk
Journal:  Oral Dis       Date:  2008-09       Impact factor: 3.511

6.  Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas.

Authors:  Sangyeul Han; Carolyn Polizzano; Gunnlaugur P Nielsen; Francis J Hornicek; Andrew E Rosenberg; Vijaya Ramesh
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

Review 7.  mTOR-understanding the clinical effects.

Authors:  A G Contreras; O Dormond; M Edelbauer; K Calzadilla; A Hoerning; S Pal; D M Briscoe
Journal:  Transplant Proc       Date:  2008-12       Impact factor: 1.066

Review 8.  Chordoma: the nonsarcoma primary bone tumor.

Authors:  Rashmi Chugh; Hussein Tawbi; David R Lucas; J Sybil Biermann; Scott M Schuetze; Laurence H Baker
Journal:  Oncologist       Date:  2007-11

Review 9.  Chordoma.

Authors:  Paolo G Casali; Silvia Stacchiotti; Claudia Sangalli; Patrizia Olmi; Alessandro Gronchi
Journal:  Curr Opin Oncol       Date:  2007-07       Impact factor: 3.645

10.  PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway.

Authors:  Zhi Y Cheng; Xiao L Guo; Xiao Y Yang; Zhi Y Niu; Shi H Li; Su Y Wang; Hao Chen; Ling Pan
Journal:  J Exp Clin Cancer Res       Date:  2008-12-30
View more
  18 in total

1.  [Novel molecular aspects of chordomas].

Authors:  S Scheil-Bertram
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  Chordoma: an update on the pathophysiology and molecular mechanisms.

Authors:  Xin Sun; Francis Hornicek; Joseph H Schwab
Journal:  Curr Rev Musculoskelet Med       Date:  2015-12

3.  High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis.

Authors:  Kai Zhang; Hao Chen; Guizhong Wu; Kangwu Chen; Huilin Yang
Journal:  Med Oncol       Date:  2014-09-27       Impact factor: 3.064

4.  Very rare diseases in oncology.

Authors:  Petr Szturz
Journal:  Med Oncol       Date:  2014-04-04       Impact factor: 3.064

5.  Reduced expression of miRNA-1237-3p associated with poor survival of spinal chordoma patients.

Authors:  Ming-Xiang Zou; Wei Huang; Xiao-Bin Wang; Jing Li; Guo-Hua Lv; Bing Wang; You-Wen Deng
Journal:  Eur Spine J       Date:  2015-04-08       Impact factor: 3.134

Review 6.  Chordoma of the Head and Neck: A Review.

Authors:  Jason K Wasserman; Denis Gravel; Bibianna Purgina
Journal:  Head Neck Pathol       Date:  2017-10-04

7.  Identification of miR-140-3p as a marker associated with poor prognosis in spinal chordoma.

Authors:  Ming-Xiang Zou; Wei Huang; Xiao-Bin Wang; Guo-Hua Lv; Jing Li; You-Wen Deng
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

8.  Low expression of PHLPP1 in sacral chordoma and its association with poor prognosis.

Authors:  Hao Chen; Kai Zhang; Guizhong Wu; Dawei Song; Kangwu Chen; Huilin Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

9.  Midterm prognosis and surgical implication for clival chordomas after extended transsphenoidal tumor removal and gamma knife radiosurgery.

Authors:  Yoshikazu Ogawa; Hidefumi Jokura; Teiji Tominaga
Journal:  BMC Neurol       Date:  2021-05-22       Impact factor: 2.474

10.  AZD8055 enhances in vivo efficacy of afatinib in chordomas.

Authors:  Tianna Zhao; I-Mei Siu; Tara Williamson; Haoyu Zhang; Chenchen Ji; Peter C Burger; Nick Connis; Jacob Ruzevick; Menghang Xia; Lucia Cottone; Adrienne M Flanagan; Christine L Hann; Gary L Gallia
Journal:  J Pathol       Date:  2021-07-28       Impact factor: 9.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.